Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data

This article was originally published in The Pink Sheet Daily

Executive Summary

One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.

Advertisement

Related Content

Teva Under Pressure As NICE Calls For More Reslizumab Analyses
On The Respiratory Horizon: A Wave Of Biologics For Asthma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register